Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 12-month Phase 1 trial data from sustained drug delivery option for anti-VEGF therapy
➤ Phase 1b results for possible topical treatment of corneal injuries
➤ Long-term safety and efficacy reinforced with 2-year clinical trial data of AMD therapy
➤ FDA accepts NDA for GA therapy
➤ NDA submitted for investigational dry eye treatment
➤ Company completes guidance meeting with FDA for dry eye drug
➤ Companies partner to conduct Phase 3 trials for possible NK treatment
➤ Partnership to develop gene therapy
➤ ASCRS news and events
➤ Study: Specific form of AMD linked to high risk of heart disease
➤ Primary endpoints achieved in study of dry eye therapy
➤ First patient enrolled in study for new pharmacologic presbyopia therapy
➤ Company submits IND for advanced AMD treatment candidate
➤ Acquisition of topical dosing technology
➤ Patent granted for oral drug candidate targeting retinal diseases
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ Phase 3 trial investigating inflammation, pain management after cataract surgery
➤ Positive topline data in study for RP gene therapy
➤ Study: Intravitreal cancer drug found to preserve vision more than traditional therapy
➤ Several studies show efficacy of home-based OCT
➤ Company announces expense reduction and refocus plan
➤ ASCRS news and events
➤ Cholesterol-lowering gene linked to risk of cataract development
➤ Study: Structure, size of individual’s visual cortex affects visual potential
➤ Purkinje reflections for capsulotomy centration
➤ Possible new therapeutic approach to treat retinitis pigmentosa
➤ ASCRS news and events
➤ FDA 510(k) clearance granted to FLACS system
➤ New genetic eye disease discovered
➤ Primary endpoint met in Phase 3 trial for dry eye drug candidate
➤ New analysis of thyroid eye disease therapy
➤ Licensing agreement for commercialization of investigational myopia therapeutic
➤ ASCRS news and events
➤ FDA approves brolucizumab injection for DME
➤ NDA filed for geographic atrophy drug
➤ Study: Dietary supplements can slow AMD progression
➤ First global study evaluates AI for diabetic retinopathy and referral uptake
➤ Plans to begin two Phase 3 trials for investigational thyroid eye disease therapy
➤ ASCRS news and events
➤ Machine assesses cardiovascular risk with retinal scan
➤ FDA requests more info for BLA for bevacizumab
➤ Genetic variables affect NMOSD treatment
➤ Study: 12-month results from canaloplasty-trabeculotomy procedure
➤ Topline results from Phase 3 pivotal trial evaluating pupil-modulating drug
➤ ASCRS news and events
➤ Topline results from Phase 3 pivotal trial evaluating mydriasis drug
➤ First person dosed in Phase 3 trial for first-in-class dry eye candidate
➤ Phase 2 study of a novel glaucoma drop targeting non-traditional outflow
➤ Digital vision screening platform with machine learning
➤ Alcon to acquire dry eye drop and inflammation/pain drop
➤ New issue online
➤ ASCRS news and events
➤ Phase 4 results evaluating intravitreal implant
➤ Interim results for X-linked retinitis pigmentosa treatment
➤ New non-contact glaucoma laser treatment receives CE mark
➤ Companies collaborate for regenerative dry eye therapy
➤ Complimentary MIGS video series
➤ ASCRS news and events
➤ 36- and 48-month efficacy demonstrated with canaloplasty
➤ Phase 1/2 trial for gene therapy for X-linked retinitis pigmentosa
➤ Topline results from Phase 2a trial for possible DME therapy
➤ Preclinical data shows potential for gene therapy to address Leber congenital amaurosis
➤ ASCRS news and events
